Ioannis Charalampopoulos | Neuroscience | Best Researcher Award

Posted on by sciencefather

Prof. Ioannis Charalampopoulos
| Neuroscience | Best Researcher Award šŸ†

Professor of Pharmacology at Medical School, University of Crete,GreecešŸŽ“

Dr. Ioannis Charalampopoulos is a distinguished Professor of Pharmacology at the University of Crete’s Medical School and a Group Leader at the Institute of Molecular Biology and Biotechnology (IMBB), Foundation of Research and Technology, Hellas (FORTH). With a focus on neuropharmacology and molecular biology, his research has contributed significantly to the study of neurodegenerative diseases, brain development, and regeneration. He has an extensive academic and research career spanning over two decades, with notable achievements in the development of novel therapeutic strategies for Alzheimerā€™s and spinal cord injury.

 

Professional ProfileĀ 

Education šŸŽ“:

  • 2021-present: Director of the Graduate Program in Neurosciences, Medical School, University of Crete
  • 2010-2023: Lecturer, Assistant and Associate Professor of Pharmacology, Medical School, University of Crete
  • 2007-2010: Researcher, Medical School, University of Crete
  • 2005-2007: Post-doctoral Fellow, Molecular Neurobiology Lab, Karolinska Institutet, Sweden
  • 2001-2005: PhD in Pharmacology, Medical School, University of Crete
  • 1998-2000: Master of Science in Neurosciences, Medical School, University of Crete
  • 1990-1996: BSc, Department of Biology, University of Patras

Work Experience šŸ’¼:

  • 2023-present: Professor of Pharmacology, Medical School, University of Crete
  • 2018-present: Researcher/Group Leader, Institute of Molecular Biology and Biotechnology (IMBB), FORTH
  • 2021-present: Director, Graduate Program in Neurosciences, Medical School, University of Crete
  • 2010-2023: Lecturer, Assistant and Associate Professor of Pharmacology, University of Crete
  • 2007-2010: Researcher, Medical School, University of Crete
  • 2005-2007: Post-doctoral Fellow, Molecular Neurobiology Lab, Karolinska Institutet, Sweden

Skills šŸ”

Dr. Charalampopoulos is highly skilled in neuropharmacology, molecular biology techniques, and neurodegenerative disease research. His expertise includes:

  • Neurotrophin receptor structure-function analysis
  • Development of therapeutic ligands for brain regeneration
  • Neurogenesis and neuroprotection strategies
  • Animal models of Alzheimerā€™s disease and spinal cord injury
  • Human iPSC-derived neural platforms for disease modeling
  • Collaborative research in neuroscience and pharmacology

Awards and Honors šŸ†

Dr. Charalampopoulos has received multiple recognitions throughout his career, including prestigious grants for his innovative work in neuroscience and neurodegenerative disease treatment:

  • HORIZON-EIC-2022 European Commission Grant: Coordinating a project on soft-robot-assisted therapeutic delivery for neurological disorders (budget: 2.9 million euros).
  • National Flagship Project: Funding for the elucidation of the genetic basis of Alzheimer’s and Parkinson’s diseases (budget: 610,000 euros).
  • Numerous research accolades, with over 80 publications in peer-reviewed journals (h-index: 35, citations >3000).

šŸ¤ Memberships:

Dr. Charalampopoulos is a member of several prestigious scientific organizations, including:

  • International Society for Neuroscience
  • European Society of Neurochemistry
  • Society for Neuroscience (SfN)
  • Greek Society for Pharmacology

Teaching Experience šŸ‘©ā€šŸ«:

Dr. Charalampopoulos has been actively involved in educating future generations of neuroscientists, particularly through his role as the Director of the Graduate Program in Neurosciences at the University of Crete. His teaching experience includes:

  • Undergraduate and postgraduate courses in pharmacology, neuropharmacology, and molecular biology.
  • Mentoring and supervising PhD students and postdoctoral researchers in pharmacology and neuroscience.
  • Developing innovative teaching methods, including the use of human stem cell models in neuroscience research.

Research Focus šŸ”¬:

Dr. Charalampopoulos’ research interests revolve around the molecular mechanisms by which growth factors and their receptors regulate the regenerative capacity of the nervous system. Key areas include:

  • Neurotrophins: Their role in brain development, neurogenesis, neuronal survival, and repair during aging.
  • Neurodegenerative Diseases: Investigating novel therapeutic strategies for Alzheimer’s disease, Parkinsonā€™s disease, and spinal cord injury.
  • Ligand Development: Creating novel ligands targeting neurotrophin receptors to enhance regenerative and neuroprotective effects.
  • Stem Cell Models: Using human induced pluripotent stem cell-derived platforms to test therapeutics for neurodegenerative diseases.
    His ultimate goal is to decipher the signaling mechanisms underlying neurodegeneration and regeneration, leading to the development of novel drugs for brain repair.
ConclusionĀ 

Dr. Ioannis Charalampopoulos is undoubtedly a top contender for the Best Researcher Award. His exceptional contributions to neuroscience, his innovative approaches in neuropharmacology, and his ability to secure substantial research funding demonstrate that he is not only an accomplished researcher but also a transformative figure in the field of neurodegenerative diseases. His strengths lie in the originality of his work, leadership in research initiatives, and mentorship in education. With slight improvements in public outreach, collaborative networks, and clinical translation, he can further elevate his already remarkable career. Therefore, Dr. Charalampopoulos is a highly deserving nominee for the Best Researcher Award, given his outstanding scientific contributions, leadership, and lasting impact on the field of neuroscience.

šŸ“š Publilcation

  • “Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer’s disease”
    • Year: 2024
    • Journal: Frontiers in Cellular Neuroscience
    • Type: Review
    • DOI: 10.3389/fncel.2024.1422130
  • “Editorial: Steroid receptors in neuron and glia”
    • Year: 2024
    • Journal: Frontiers in Endocrinology
    • Type: Editorial
    • DOI: 10.3389/fendo.2024.1472908
  • “Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimerā€™s disease”
    • Year: 2024
    • Journal: Stem Cell Research & Therapy
    • Type: Journal Article
    • DOI: 10.1186/s13287-024-03818-w
  • “Cover Image, Volume 72, Issue 4”
    • Year: 2024
    • Journal: Glia
    • Type: Journal Article
    • DOI: 10.1002/glia.24399
  • “Dynamics of myelin deficits in the 5xFAD mouse model for Alzheimer’s disease and the protective role of BDNF”
    • Year: 2024
    • Journal: Glia
    • Type: Journal Article
    • DOI: 10.1002/glia.24505
  • “Multimodal beneficial effects of BNN27, a Nerve Growth Factor synthetic mimetic, in the 5xFAD mouse model of Alzheimerā€™s Disease”
    • Year: 2024
    • Type: Preprint
    • DOI: 10.21203/rs.3.rs-3886007/v1
  • “Development of Pleiotropic TrkB and 5-HT<sub>4</sub> Receptor Ligands as Neuroprotective Agents”
    • Year: 2024
    • Journal: Molecules
    • Type: Journal Article
    • DOI: 10.3390/molecules29020515
  • “Butanolides and Butenolides from a Marine-Derived Streptomyces sp. Exert Neuroprotective Activity through Activation of the TrkB Neurotrophin Receptor”
    • Year: 2023
    • Journal: Marine Drugs
    • Type: Journal Article
    • DOI: 10.3390/md21090465
  • “Neurotrophin Analog ENT-A044 Activates the p75 Neurotrophin Receptor, Regulating Neuronal Survival in a Cell Context-Dependent Manner”
    • Year: 2023
    • Journal: International Journal of Molecular Sciences
    • Type: Journal Article
    • DOI: 10.3390/ijms241411683
  • “Neurotrophin Analog ENT-A044 Activates the p75 Neurotrophin Receptor Promoting Cell Death in Mouse and Human Neuronal Cells”
    • Year: 2023
    • Type: Preprint
    • DOI: 10.20944/preprints202306.1633.v1

Dr. Amira Boseila | Neuroscience| Best Researcher Award

Posted on by sciencefather

Dr. Amira Boseila | Neuroscience| Best Researcher AwardšŸ†


Lecturer at Sinai University,EgyptšŸŽ“

Dr. Amira Abdel Halim Hamada Boseila is a full-time lecturer in Pharmaceutical Sciences at Sinai University, Egypt, where she teaches advanced courses in drug delivery systems and pharmaceutics. She also serves as a post-doctoral researcher at the National Organization for Drug Control and Research (NODCAR) and the Egyptian Drug Authority. With a PhD from Cairo University, her research focuses on nanomedicine, drug targeting, and innovative drug delivery systems. Dr. Boseila has contributed to several impactful publications and is actively involved in various research projects aimed at enhancing therapeutic strategies.

 

Professional ProfileĀ 

šŸŽ“ Education

Dr. Amira Abdel Halim Hamada Boseila holds a Doctor of Philosophy in Pharmaceutical Sciences from the Faculty of Pharmacy at Cairo University, awarded in February 2020, with a thesis focused on the utility of nanocarriers for targeted delivery of an antiviral drug to the liver. She also earned a Master of Pharmaceutical Sciences from Cairo University in December 2013, where her thesis was centered on the formulation and evaluation of a modified nasal drug delivery system for the antiemetic drug ondansetron. Additionally, she completed a Total Quality Management Diploma at the American University of Cairo in 2009, further enhancing her expertise in quality control management. Her academic journey began with a Bachelor of Pharmaceutical Sciences from Cairo University, graduating in May 2007 with a grade of very good. She attended La Rose De Lisieux/Language School in Dokkie, where she completed her high school education with a focus on science from September 1990 to June 2002.

 

šŸ¢ Work Experience

Full-time lecturer at the Faculty of Pharmacy, Sinai University since September 2022, and post-doctoral researcher at NODCAR and the Egyptian Drug Authority since July 2020. Previously held positions as lead quality control specialist and head of the Comparative Dissolution Unit. Guest lecturer on drug targeting at Ain Shams University since October 2020

šŸ§¬ Skills

Expertise in novel drug delivery systems, nanomedicine, drug targeting, pharmacokinetics, comparative dissolution studies, and quality by design

Awards and Honors šŸ†

Recognized for contributions to pharmaceutical research through impactful publications and ongoing collaborations with prestigious institutions, including funded research projects from the University of Hail and Misr El Kheir Foundation

šŸ”¬ Research Focus

Dedicated to advancing nanomedicine and innovative drug delivery systems, with a focus on developing targeted therapies and modified release dosage forms. Actively involved in projects aimed at repurposing anti-inflammatory agents and formulating virucidal throat sprays

šŸ“š PublicationĀ 

  • Impact of Lyophilized Milk Kefir-Based Self-Nanoemulsifying System on Cognitive Enhancement via the Microbiotaā€“Gutā€“Brain Axis
    Author: Amira Boseila
    Citation: MDPI, 2023
  • Throat Spray Formulated with Virucidal Pharmaceutical Excipients as an Effective Early Prophylactic or Treatment Strategy Against Pharyngitis Post-Exposure to SARS-CoV-2
    Author: Amira Boseila
    Citation: ScienceDirect, 2024
  • Antidepressive and Cardioprotective Effects of Self-Nanoemulsifying Self-Nanosuspension Loaded with Hypericum Perforatum on Post-Myocardial Infarction Depression in Rats
    Author: Amira Boseila
    Citation: Springer, 2022
  • Recent Advances in Adsorptive Nanocomposite Membranes for Heavy Metals Ion Removal from Contaminated Water: A Comprehensive Review
    Author: Amira Boseila
    Citation: MDPI, 2023
  • Iron Oxide Nanoparticles-Plant Insignia Synthesis with Favorable Biomedical Activities and Less Toxicity, in the ā€œEra of the-Greenā€: A Systematic Review
    Author: Amira Boseila
    Citation: NIH, 2023
  • In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity
    Author: Amira Boseila
    Citation: PubMed, 2023
  • Superiority of DEAE-Dx-Stabilized Cationic Bile-Based Vesicles over Conventional Vesicles for Enhanced Hepatic Delivery of Daclatasvir
    Author: Amira Boseila
    Citation: Molecular Pharmaceutics, 2023
  • Design of Bile-Based Vesicles (BBVs) for Hepatocytes Specific Delivery of Daclatasvir: Comparison of Ex-Vivo Transenterocytic Transport, In-Vitro Protein Adsorption Resistance, and HepG2 Cellular Uptake of Charged and Ī²-Sitosterol Decorated Vesicles
    Author: Amira Boseila
    Citation: PubMed, 2023
  • Preparation and Characterization of Thermosensitive Mucoadhesive In-Situ Gels for Nasal Delivery of Ondansetron Hydrochloride
    Authors: A.A. Boseila, A.Y. Abdel-Reheem, G. Abdelbary
    Citation: Al-Azhar Journal of Pharmaceutical Sciences, 2014